肠道屏障破坏与黏膜免疫失调促进慢性肾脏病肾纤维化
该研究在5/6肾切除CKD小鼠中发现肠道屏障破坏(漏肠)伴结肠HSP70和claudin-1表达下降、claudin-2表达和凋亡增加,以及黏膜免疫失调(CX3CR1中间/高巨噬细胞比值升高)。口服乳杆菌混合物部分修复肠道屏障、恢复巨噬细胞比值并增加调节性树突状细胞,从而抑制全身炎症和肾纤维化。
要点
- CKD小鼠存在肠道屏障破坏和黏膜免疫失调,与全身炎症和肾纤维化相关。
- 口服乳杆菌可部分修复肠道屏障并调节黏膜免疫,减轻肾纤维化。
- 靶向肠道可能为CKD提供新的治疗机会。
核心结论
- 肠道菌群失调相关的肠道屏障破坏和黏膜免疫异常是CKD全身炎症和进行性纤维化的重要因素。
- 靶向肠道可能为CKD提供新的治疗机会。
研究设计与样本
- 6周龄小鼠通过5/6肾切除术诱导CKD,并喂食乳杆菌混合物8周。
- 收集血清、尿液和粪便样本进行肾功能评估和肠道微生物组分析。
- 评估肠道通透性、结肠HSP70和结肠上皮完整性,测量结肠和肾脏细胞因子水平。
- 通过流式细胞术分析结肠白细胞,并将骨髓来源细胞与乳杆菌混合物共培养。
主要发现
- CKD小鼠出现「漏肠」,伴结肠HSP70和claudin-1表达下降,而孔形成性claudin-2表达和凋亡增加。
- CKD小鼠结肠中调节性T细胞百分比与对照无差异,但细胞因子表达和CX3CR1中间:CX3CR1高促炎/驻留巨噬细胞比值升高。
- 口服乳杆菌部分缓解CKD诱导的「漏肠」,恢复结肠上皮HSP70、claudin-1和claudin-2表达并减少凋亡。
- 益生菌治疗恢复CX3CR1中间:CX3CR1高巨噬细胞比值并增加结肠CD103+CD11c+调节性树突状细胞。
- 上述变化抑制全身炎症和肾纤维化。
临床怎么用
- 对于CKD患者,可关注肠道屏障功能和黏膜免疫状态,但益生菌治疗需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging evidence suggests that intestinal dysbiosis is associated with diverse pathological processes. In this study we demonstrated intestinal barrier disruption and aberrant mucosal immunity in 5/6 nephrectomized mice and the effect of probiotics on chronic kidney disease (CKD). METHODS: CKD was induced in 6-week-old mice by 5/6 nephrectomy. They were fed a lactobacilli mixture for 8 weeks. Serum, urine and stool samples were collected for renal function assessments and gut microbiome analyses. Gut permeability, colon heat shock protein 70 (HSP70) and colon epithelial integrity were evaluated and cytokine levels in colon and kidney were measured. Colon leukocytes were analyzed by flow cytometry and bone marrow-derived cells were cocultured with lactobacilli mixture. RESULTS: In CKD mice, 'leaky gut' was accompanied by decreased colon HSP70 and claudin-1 expression, whereas it increased pore-forming claudin-2 expression and apoptosis. Although the percentage of regulatory T cells did not differ between CKD and control mice, cytokine expression and the ratio of CX3CR1intermediate:CX3CR1high pro-inflammatory/resident macrophages increased in the colon of CKD mice. Orally administered lactobacilli partially mitigated the CKD-induced 'leaky gut'; restored colon epithelial HSP70, claudin-1 and claudin-2 expression and decreased apoptosis. Probiotic treatment also restored the CX3CR1intermediate:CX3CR1high macrophage ratio and increased circular dichroism (CD)103+CD11c+ regulatory dendritic cells in the colon. These changes suppressed systemic inflammation and kidney fibrosis. CONCLUSIONS: Our results suggest that intestinal dysbiosis-associated gut barrier disruption and aberrant mucosal immunity are important for the systemic inflammation and progressive fibrosis of CKD. Targeting the intestine might provide novel therapeutic opportunities for CKD.
引用
- Yang J, Lim SY, Ko YS, et al. Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease. Nephrol Dial Transplant. 2019. PMID: 29939312. doi:10.1093/ndt/gfy172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。